ALGS Stock Summary and Trading Ideas (Aligos Therapeutics | NASDAQ:ALGS)

Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Aligos Therapeutics trades on the NASDAQ stock market under the symbol ALGS.

As of December 26, 2025, ALGS stock price declined to $10.11 with 29,481 million shares trading.

ALGS has a beta of 2.28, meaning it tends to be more sensitive to market movements. ALGS has a correlation of 0.11 to the broad based SPY ETF.

ALGS has a market cap of $62.21 million. This is considered a Micro Cap stock.

Last quarter Aligos Therapeutics reported $741,000 in Revenue and -$3.04 earnings per share. This beat revenue expectation by $241,000 and missed earnings estimates by -$1.00.

In the last 3 years, ALGS traded as high as $60.25 and as low as $3.76.

The top ETF exchange traded funds that ALGS belongs to (by Net Assets): VTI, VXF, AVSC, DCOR.

ALGS has underperformed the market in the last year with a price return of -76.7% while the SPY ETF gained +16.0%. ALGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +3.3% and -24.0%, respectively, while the SPY returned +4.6% and +1.5%, respectively.

ALGS support price is $9.84 and resistance is $11.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALGS shares will trade within this expected range on the day.